<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509300</url>
  </required_header>
  <id_info>
    <org_study_id>AMCPHO-SCT0902</org_study_id>
    <nct_id>NCT01509300</nct_id>
  </id_info>
  <brief_title>HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors</brief_title>
  <official_title>HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Globulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Conditioning with total body irradiation (TBI) and fludarabine, cyclophosphamide
      and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the
      setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition,
      T-cell depletion may contribute to prevent developing severe acute graft versus host disease
      (GVHD) in haploidentical transplantation.

      PURPOSE: This phase I/II trial is to evaluate the safety and efficacy of TBI, fludarabine,
      cyclophosphamide and antithymocyte globulin with T-cell depleted graft from haploidentical
      donors in treating patients with acute leukemia and myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplantation-related mortality and overall survival of TBI, Fludarabine, Cyclophosphamide and anti-thymocyte globulin for engraftment of CD3 depleted haploidentical peripheral blood stem cells.</measure>
    <time_frame>2 years post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment and graft failure rates</measure>
    <time_frame>28 days engraftment and graft failure</time_frame>
    <description>Number of patients who failed to stable engraftment by 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Number of patients with acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Number of death after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate and overall survival</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>HAPLO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>On days -10 to -9</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Beginning on day 4 and continuing until blood counts recover</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>2Gy D-6 to D-4</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/M2 once daily IV on days -8 to -4</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>60 mg/kg IV on day-3 and -2</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>begin on 0</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>begin on 0</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 on day +21</description>
    <arm_group_label>HAPLO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Disease characteristics

               -  Acute lymphoblastic leukemia (first remission, high risk; beyond first remission;
                  refractory)

               -  Acute myeloblastic leukemia (first remission, high risk; beyond first remission;
                  refractory)

               -  Myelodysplastic syndrome

               -  Solid tumors (Refractory/relapse)

          2. No HLA-identical family member or closely matched (8 or 7 of 8 HLA-locus match)
             unrelated marrow donor available

          3. HLA-haploidentical related donor available

        Exclusion criteria

          1. Active fungal infections

          2. HIV positive

          3. Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Joon Im, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Joon Im, MD &amp; PhD</last_name>
    <phone>82-2-3010-3371</phone>
    <email>hojim@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Joon Im, MD &amp; PhD</last_name>
      <phone>82-2-3010-3371</phone>
      <email>hojim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Ho Joon Im, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol. 2012 Apr;157(1):139-42. doi: 10.1111/j.1365-2141.2011.08924.x. Epub 2011 Nov 5.</citation>
    <PMID>22055111</PMID>
  </reference>
  <reference>
    <citation>Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S54-9. doi: 10.1038/bmt.2008.285. Review.</citation>
    <PMID>18978746</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Joon Im</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>CD3 depletion</keyword>
  <keyword>Children and adolescents</keyword>
  <keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

